**Chartered Accountants** 

5th Floor, Lodha Excelus, Apollo Mills Compound N. M. Joshi Marg, Mahalaxmi Mumbai - 400 011 India Telephone +91 (22) 4345 5300 Fax +91 (22) 4345 5399

Limited review report on unaudited quarterly and year-to-date standalone financial results of Advanced Enzyme Technologies Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

# To the Board of Directors of Advanced Enzyme Technologies Limited

We have reviewed the accompanying statement of unaudited standalone financial results of Advanced Enzyme Technologies Limited ('the Company') for the quarter ended 30 September 2018 and the year-to-date results for the period from 01 April 2018 to 30 September 2018 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP** *Chartered Accountants* Firm's Registration No: 101248W/W-100022

Sadashiv Shetty Partner Membership No: 048648

Mumbai 1 November 2018

> B S R & Co (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability, Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

Registered Office: 5th Floor, Lodha Excelus Apollo Mills Compound N. M. Joshi Marg, Mahalaxmi Mumbai - 400 011. India

Advanced Enzyme Technologies Limited CIN No.: L24200MH1989PLC051018 Regd, Olfice and Corporate Olfice: Sun Magnetica, Sth Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India. Tel No:91-22-41703220 Fax No: 491-2225835159 Website: www.advancedenzymes.com, Ernail Id :sanjay@advancedenzymes.com

Statement of unaudited standalone financial results for the quarter and six months ended 30 September 2018

			(₹ in Million except per share data)				
			Quarter ended			s ended	Year ended
Particul	ars	30-Sep-18 Unaudited	30-Jun-18 Unaudited	30-Sep-17 Unaudited	30-Sep-18 Unaudited	30-Sep-17 Unaudited	31-Mar-18 Audited
1 Revenue	e from operations (refer note ii)	585.67	540.42	491.67	1,126.08	974.70	2,153.05
2 Other In	come	30.11	7.21	23.58	37.33	25.38	50.52
3 Total In	come (1+2)	615,78	547.63	515,25	1,163.41	1,000.08	2,203.57
4 Expense							
(a) C	ost of materials consumed	153.27	245.71	225.25	398.98	430.28	847_0
(b) Pi	urchases of stock-in-trade	-					
(c) CI	hanges in inventories of finished goods, work-in-progress and stock-in-trade	95.96	(63,99)	32.39	31,97	4.50	8.12
(d) Ex	xcise duty		1.40			32.45	32.45
	mployee benefits expense	81.91	90.05	76.27	171.96	163.38	324.8
(f) Fi	nance costs	18.41	9.26	9.35	27.67	16.76	30.60
	epreciation and amortisation expense	21.26	20.84	19.23	42.10	38,15	78.1
	ther expenses	126.18	104.58	83.81	230,76	174.39	444.0
Total Ex	penses	496,99	406.45	446.30	903.44	859,91	1,765.1
5 Profit be	afore Exceptional item and tax (3-4)	118,79	141.18	68,95	259,97	140,17	438,4
6 Exceptio	nal item						
7 Profit be	efore tax (5-6)	118,79	141.18	68.95	259,97	140,17	438.41
8 Tax expe	ense						
	urrent tax	29.88	35.09	13,74	64.97	33,43	93.78
	eferred tax charge/(credit)	0.39	(2.47)	1.07	(2.08)	1.80	(14.27
	( expense	30.27	32.62	14.81	62.89	35.23	79.5
	it for the period (7-8)	88.52	108,56	54.14	197.08	104.94	358,90
	omprehensive income						-
	is that will not be reclassified to Statement of Profit and Loss	1.64	0.76	(0.14)	2.40	(5.00)	2.37
	ome tax related to items that will not be reclassified to Statement of Profit and Loss	(0.48)	(0.22)	0.05	(0.70)	1.73	(0.82
	is that will be reclassified to Statement of Profit and Loss			8	-		
	ome tax related to items that will be reclassified to Statement of Profit and Loss	(i) (i)	· ·			•	
Total Ot	her comprehensive income	1.16	0.54	(0.09)	1.70	(3.27)	1.55
14 J. J.							
11 I otal co	niprehensive income (9+10)	89.68	109.10	54.05	198.78	101.67	360.45
	Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.30	223,30	223.26	223.30	223.26	223.26
13 Other eq							2,665.72
	s Per Share of ₹ 2 each (not annualized)						
	(Basic)	0.80	0,97	0,48	1.77	0.94	3 22
(b) ₹	(Diluted)	0.79	0.97	0.48	1.76	0.93	3.21





ces. w. Kahra

Advanced Enzyme Technologies Limited CIN No.: L24200MH1989PLC051018 Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India. Tel No:91-22-4170320 Fax No: +91-22-25835159 Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

## Statement of standalone assets and liabilities

Particulars	As at	As at	
	30 Sep 2018	31 Mar 2018	
	Unaudited	Audited	
ASSETS			
(1) Non-current assets			
(a) Property, Plant and Equipment	951.89	976.0	
(b) Capital work-in-progress	33.84	24.2	
(c) Other Intangible assets	22,00	2.0	
(d) Intangible assets under development	61.23	78	
(e) Financial Assets	01.23	70,	
(i) Investments	1,203,40	1.200.3	
(ii) Loans	339.22	293	
		293,	
(iii) Other financial assets	0.04		
(f) Income tax asset (net)	51.14	51.	
(g) Other non-current assets	11,30	13.	
Total non-current assets	2,674.06	2,640.	
(2) Current Assets			
(a) Inventories	575,41	548.6	
(b) Financial Assets			
(i) Trade receivables	428,43	385	
(ii) Cash and cash equivalents	4.30	1.1	
(iii) Bank balances other than (ii) above	20.11	2.9	
(iv) Loans	0.23	20.	
(v) Other financial assets	32.81	30.9	
(c) Other current assets	56.85	51.0	
Total current assets	1,118.14	1,041.7	
(3) Non-current assets held for sale	48.17	48,1	
Total assets	3,840.37	3,729.9	
EQUITY AND LIABILITIES			
(1) Equity			
(a) Equity share capital	223.30	223.2	
(b) Other equity	2,813.28	2,665.7	
Total equity	3,036.58	2,888.5	
(2) Non-current llabilities			
(a) Financial liabilities			
(i) Borrowings	53 90	79.4	
(b) Provisions	4	5.5	
(c) Deferred tax liabilities (net)	26.21	15.2	
Total non-current liabilities	80.11	100.2	
(3) Current liabilities			
(a) Financial liabilities			
(i) Borrowings	007.00		
(ii) Trade payables	287.80	323 2	
		212.0	
(iii) Other financial Liabilities	138.62	123 7	
(b) Other current liabilities	32.99	15 1	
(c) Provisions	14.03	17.9	
(d) Current tax liabilities (net)	24.44	7.8	
	678.08	700.1	
Total current liabilities			
Total current liabilities (4) Liabilities for non-current assets held for sale	45.60	40.6	





co w.Kahra

### Advanced Enzyme Technologies Limited CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

#### Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

### Notes:

(i) The above unaudited standalone financial results for the quarter and six months ended 30 September 2018 of Advanced Enzyme Technologies Limited ('the Company') were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 1 November 2018. The statutory auditors of the Company have carried out limited review of the above unaudited standalone financial results pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015. The Limited Review report does not have any qualifications. The Limited Review report will be filed with stock exchanges and will be available on the Company's website.

(ii) According to the requirements of Ind AS and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, revenue for the corresponding previous six months ended 30 September 2017 and year ended 31 March 2018 were and are reported inclusive of Excise Duty. The Government of India had implemented Goods and Service Tax ('GST') from 1 July 2017, replacing Excise Duty, Service Tax and various other indirect taxes. As per Ind AS 18, the revenue for the quarter ended 30 September 2018, 30 September 2017 and 30 June 2018 and year ended 31 March 2018 are reported net of GST, Had the previously reported revenues were shown net of Excise Duty, comparative revenue of the Company would have been as follows:

	(₹ in Million)			
Particulars	Six months e	Growth %		
	30-Sep-18	30-Sep-17		
Revenue from operations	1,126.08	943.82	19%	

(iii) The Company operates only in one primary business segment viz, 'manufacturing and sales of enzymes',

(iv) The shareholders in its meeting held on 14 September 2018 have approved the final dividend for the financial year 2017-18 of Rs 0.50 per equity share and the same was paid on 18 September 2018.

(v) Effective 1 April 2018, the Company has adopted Ind AS 115 'Revenue from Contracts with Customers'. Based on the assessment done by management, there is no material impact on the revenue recognised.

(vi) During the six months ended 30 September 2018, the Company has allotted 18,800 equity shares to employees under the 'AETL Employee Stock Option Scheme 2015'- ("AETL ESOS 2015").

(vii) On 10 July 2018, the Company has purchased 100,000 ordinary shares of RM (Malaysian Ringitt) 1.00 each of Advanced Enzymes (Malaysia) Sdn. Bhd. by way of subscription to the rights issue, equivalent to ₹ 1.78 million.

Place: Thane Dated: 1 November 2018





By Order of the Board of Directors For Advanced Enzyme Technologies Limited CIN: L24200MH1989PLC051018

W. W. Kabra

M. M. Kabra Wholetime Director DIN : 00148294